Omvoh: A Novel Era in Crohn’s Disease and Ulcerative Colitis Treatment?
New long-term data unveiled on February 19, 2026, demonstrate the sustained efficacy of Omvoh (mirikizumab-mrkz) in adults with moderately to severely active Crohn’s disease. Presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) in Stockholm, the findings suggest a potential shift in how these chronic inflammatory bowel diseases (IBD) are managed.
Durable Remission and Reduced Complications
The Phase 3 VIVID-2 open-label extension study revealed that over 90% of Crohn’s disease patients who achieved steroid-free remission after one year maintained that control through three years. What we have is a significant finding, as maintaining remission is a key challenge for individuals with Crohn’s. Omvoh-treated patients across both Crohn’s disease and ulcerative colitis (UC) experienced remarkably low rates of hospitalizations, and surgeries. This suggests the drug not only controls symptoms but may also prevent the need for more invasive interventions.
First-in-Class Efficacy and Consistent Dosing
Omvoh is unique in its class as the only IL-23p19 inhibitor demonstrating strong and durable efficacy with a simple, consistent monthly dosing schedule over four years in UC and three years in Crohn’s disease. This consistency could improve patient adherence and simplify treatment plans. The data highlight a 92.4% clinical remission rate at 152 weeks among patients who achieved endoscopic response at one year, and a 91.2% corticosteroid-free clinical remission rate over the same period.
Beyond Remission: Improving Quality of Life
The benefits of Omvoh extend beyond simply achieving remission. A significant 82.1% of patients experienced a greater than or equal to three-point reduction on the Urgency Numeric Rating Scale (UNRS), and 71.7% reported a UNRS score of 2 or less. This indicates a substantial improvement in bowel urgency, a symptom that significantly impacts daily life for many IBD sufferers. As Dr. Edward Barnes of the University of North Carolina at Chapel Hill noted, these results offer confidence that Omvoh can help patients achieve and maintain long-term outcomes, including intestinal healing.
Impact on the IL-23p19 Inhibitor Landscape
Omvoh’s success is reshaping the landscape of IBD treatment. By selectively targeting the IL-23p19 subunit, the drug inhibits the IL-23 pathway, a key driver of inflammation in IBD. The long-term data builds upon previously disclosed two-year results in Crohn’s disease and four-year results in UC, solidifying Omvoh’s position as a leading treatment option.
Safety Profile and Regulatory Approvals
The long-term safety profile of Omvoh appears consistent with previous findings. Common adverse events included COVID-19, nasopharyngitis, and upper respiratory tract infection. Omvoh has received regulatory approvals in 47 countries for the treatment of moderately to severely active UC and Crohn’s disease.
Frequently Asked Questions (FAQ)
What is IL-23p19? IL-23p19 is a protein that plays a critical role in intestinal inflammation associated with Crohn’s disease and ulcerative colitis.
How does Omvoh work? Omvoh selectively targets and inhibits the IL-23p19 subunit, reducing inflammation in the gastrointestinal tract.
What is the VIVID-2 study? VIVID-2 is a Phase 3 open-label extension study evaluating the long-term effects of Omvoh in Crohn’s disease patients.
Is Omvoh suitable for all Crohn’s disease patients? Omvoh is indicated for adults with moderately to severely active Crohn’s disease. A healthcare professional should determine if it’s the right treatment option.
Pro Tip
Discuss the potential benefits and risks of Omvoh with your gastroenterologist to determine if it aligns with your individual treatment goals and medical history.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
To learn more about Omvoh, including prescribing information and a medication guide, please visit Lilly’s website.
